Skip to main content
SpringerLink
Log in

Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Olmesartan medoxomil (OLM)-based antihypertensive treatment is a valuable option in the treatment of patients with mild to severe hypertension, including those with difficult-to-treat disease. Once-daily OLM, as monotherapy or in combination with hydrochlorothiazide (HCT) and/or amlopidine (AML), provides blood pressure (BP) control over the entire 24-h dosing interval, reduces systolic and diastolic BP, enables patients to achieve BP goals and is generally well tolerated. In patients who require treatment with two or more antihypertensives, treatment with fixed-dose combinations (FDC) of OLM (an angiotensin II receptor blocker) + AML (a calcium channel blocker) and/or HCT (a diuretic) is a rational choice, as the drugs have complementary mechanisms of action, and the use of FDCs reduces pill burden, which may improve patient adherence and persistence to treatment, and clinical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.

    Article  CAS  PubMed  Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

    Article  CAS  PubMed  Google Scholar 

  3. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167(2):141–7.

    Article  PubMed  Google Scholar 

  4. Erdine S. How do compliance, convenience, and tolerability affect blood pressure goal rates? Am J Cardiovasc Drugs. 2012;12(5):295–302.

    CAS  PubMed  Google Scholar 

  5. Olmetec (olmesartan medoxomil) film-coated tablets: UK summary of product characteristics. Gerrards Cross; Daiichi Sankyo UK Limited; 2015.

  6. Benicar (olmesartan medoxomil) tablets: US prescribing information. Parsippany (NJ): Daiichi Sankyo, Inc.; 2016.

  7. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin. 2008;24(8):2389–401.

    Article  CAS  PubMed  Google Scholar 

  8. Xie L, Frech-Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014;30(12):2415–22.

    Article  CAS  PubMed  Google Scholar 

  9. Olmetec Plus (olmesartan medoxomil + hydrochlorothiazide) film-coated tablets: UK summary of product characteristics. Gerrards Cross; Daiichi Sankyo UK Limited; 2015.

  10. Benicar HCT (olmesartan medoxomil + hydrochlorothiazide) tablets: US prescribing information. Parsippany (NJ): Daiichi Sankyo, Inc.; 2016.

  11. Sevikar (olmesartan medoxomil + amlodipine besilate): UK summary of product characteristics. Gerrards Cross: Daiichi Sankyo UK Limited; 2015.

  12. Azor (olmesartan medoxomil + amlodipine) tablets: US prescribing information. Parsippany (NJ): Daiichi Sankyo, Inc.; 2016.

  13. Sevikar HCT (olmesartan medoxomil + amlodipine besilate + hydrochlorothiazide): UK summary of product characteristics. Gerrards Cross: Daiichi Sankyo UK Limited; 2015.

  14. Tribenzor HCT (olmesartan medoxomil + amlodipine + hydrochlorothiazide) tablets: US prescribing information. Parsippany (NJ): Daiichi Sankyo, Inc.; 2016.

  15. Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;285(2):181–8.

    Article  CAS  PubMed  Google Scholar 

  16. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9):1239–72.

    Article  CAS  PubMed  Google Scholar 

  17. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens. 2001;19(Suppl 1):15–20.

    Article  Google Scholar 

  18. Neutel JM, Elliott WJ, Izzo JL Jr, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens. 2002;4(5):325–31.

    Article  CAS  Google Scholar 

  19. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23(7):419–30.

    Article  CAS  Google Scholar 

  20. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens. 2001;19(Suppl 1):49–56.

    Article  Google Scholar 

  21. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3(5):283–91.

    Article  CAS  Google Scholar 

  22. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens. 2007;9(3):187–95.

    Article  CAS  Google Scholar 

  23. Flack JM, Graff A, Li W, et al. Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. Postgrad Med. 2012;124(3):59–70.

    Article  PubMed  Google Scholar 

  24. Wang L, Jian-wei Zhao, Liu B, et al. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers. Am J Cardiovasc Drugs. 2012;12(5):335–44.

    Article  CAS  PubMed  Google Scholar 

  25. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens. 2003;17(6):425–32.

    Article  CAS  PubMed  Google Scholar 

  26. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens. 2002;16(Suppl 2):24–8.

    Article  Google Scholar 

  27. Omboni S, Malacco E, Mallion JM, et al. Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines. Clin Interv Aging. 2015;10:1575–86.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Malacco E, Omboni S, Volpe M, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens. 2010;28(11):2342–50.

    Article  CAS  PubMed  Google Scholar 

  29. Wang JG, Sun NL, Ke YN, et al. Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements. Clin Drug Investig. 2012;32(11):729–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jiao Y, Ke Y, Sun N, et al. Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension: a multicenter, open-label, single treatment group clinical study. Eur Rev Med Pharmacol Sci. 2012;16(5):653–9.

    PubMed  Google Scholar 

  31. Brunner HR. Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag. 2006;2(4):327–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kario K, Saito I, Kushiro T, et al. Effects of olmesartan-based treatment on masked, white-coat, poorly controlled, and well-controlled hypertension: HONEST study. J Clin Hypertens (Greenwich). 2014;16(6):442–50.

    Article  CAS  Google Scholar 

  33. Hazan L, Hernandez Rodriguez OA, Bhorat AE, et al. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55(6):1323–30.

    Article  CAS  PubMed  Google Scholar 

  34. Chrysant SG, Chavanu KJ, Xu J. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am J Cardiovasc Drugs. 2009;9(4):241–51.

    Article  CAS  PubMed  Google Scholar 

  35. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich). 2008;10(12):911–21.

    Article  CAS  Google Scholar 

  36. Chrysant SG, Weber MA, Wang AC, et al. Evaulation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17(3):252–9.

    Article  CAS  PubMed  Google Scholar 

  37. Kereiakes DJ, Maa J-F, Shojaee A, et al. Effects of an olmesartan medoxomil-based treatment algorithm of systolic blood pressure in patients with stage 1 or 2 hypertension. Am J Cardiovasc Drugs. 2010;20(4):239–46.

    Article  Google Scholar 

  38. Neutel JM, Kereiakes DJ, Waverczak WF, et al. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin. 2010;26(3):721–8.

    Article  CAS  PubMed  Google Scholar 

  39. Fogari R, Tadde S, Holm-Bentzen M, et al. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Clin Drug Investig. 2010;30(9):581–97.

    Article  CAS  PubMed  Google Scholar 

  40. Rump LC, Girerd X, Sellin L, et al. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens. 2011;25(9):565–74.

    Article  CAS  PubMed  Google Scholar 

  41. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST study. Clin Drug Investig. 2007;27(8):545–58.

    Article  CAS  PubMed  Google Scholar 

  42. Rump LC, Ambrosioni E, Burnier M, et al. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens. 2006;20(4):299–301.

    Article  CAS  PubMed  Google Scholar 

  43. Kereiakes DJ, Neutel JM, Punzi HA, et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs. 2007;7(5):361–72.

    Article  CAS  PubMed  Google Scholar 

  44. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587–604.

    Article  CAS  PubMed  Google Scholar 

  45. Volpe M, Brommer P, Haag U, et al. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Invest. 2009;29(1):11–25.

    Article  CAS  Google Scholar 

  46. Barrios V, Brommer P, Haag U, et al. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(7):427–39.

    Article  CAS  PubMed  Google Scholar 

  47. Zhu J-R, Zhang S-Y, Gao P-J. Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. Arch Pharm Res. 2014;37(12):1588–98.

    Article  CAS  PubMed  Google Scholar 

  48. Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens (Greenwich). 2011;13(6):404–12.

    Article  CAS  Google Scholar 

  49. Oparil S, Lee J, Karki S, et al. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol. 2009;54(5):427–36.

    Article  CAS  PubMed  Google Scholar 

  50. Schmieder RE, Böhm M. Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens. 2011;25(6):354–63.

    Article  CAS  PubMed  Google Scholar 

  51. Chrysant SG, Lee J, Melino M, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010;24(11):730–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Oparil S, Chrysant SG, Melino M, et al. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens. 2010;24(12):831–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ding S, Liu J, Fu Q, et al. Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension. Arch Gerontol Geriatr. 2013;57(3):423–7.

    Article  CAS  PubMed  Google Scholar 

  54. Hsueh WA, Shojaee A, Maa JF, et al. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Curr Med Res Opin. 2012;28(11):1809–18.

    Article  CAS  PubMed  Google Scholar 

  55. Nesbitt SD, Shojaee A, Maa JF, et al. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). J Hum Hypertens. 2013;27(7):445–52.

    Article  CAS  PubMed  Google Scholar 

  56. Nesbitt S, Shojaee A, Maa JF. Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy. J Clin Hypertens (Greenwich). 2013;15(4):247–53.

    Article  CAS  Google Scholar 

  57. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich). 2009;11(9):475–82.

    Article  CAS  Google Scholar 

  58. Neutel J, Shojaee A, Maa JF. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy. Adv Ther. 2012;29(6):508–23.

    Article  CAS  PubMed  Google Scholar 

  59. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252–69.

    Article  CAS  PubMed  Google Scholar 

  60. Volpe M, Christian Rump L, Ammentorp B, et al. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012;32(10):649–64.

    Article  CAS  PubMed  Google Scholar 

  61. Sohn IS, Kim C-J, On B-H, et al. Efficacy and safety study of olmesartan medoxomil, amlodipine, and hydrochlorothiazide combination therapy in patients with hypertension not controlled with olmesartan medoxomil and hydrochlorothiazide combination therapy: results of a randomized, double-blind, multicenter trial. Am J Cardiovasc Drugs. 2016;16(2):129–38.

    Article  CAS  PubMed  Google Scholar 

  62. Rump LC, Ammentorp B, Laeis P, et al. Adding hydrochlorothiazide to olmesartan/amlodipine increases efficacy in patients with inadequate blood pressure control on dual-combination therapy. J Clin Hypertens (Greenwich). 2016;18(1):60–9.

    Article  CAS  Google Scholar 

  63. Lewin AJ, Izzo JL Jr, Melino M, et al. Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. Drugs Aging. 2013;30(7):549–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Chrysant SG, Littlejohn T III, Izzo JL Jr, et al. Triple combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in Black and non-Black study participants with hypertension: the TRINITY randomized, double-blind 12-week, parallel-group study. Am J Cardiovasc Drugs. 2012;12(4):233–43.

    Article  CAS  PubMed  Google Scholar 

  65. Lewin AJ, Kereiakes DJ, Chrysant SG, et al. Triple-combination treatment with olmesartan medoxomil/amlodipine/hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study. Ethn Dis. 2014;24(1):41–7.

    PubMed  Google Scholar 

  66. Roth EM, Oparil S, Melino M, et al. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich). 2013;15(8):584–92.

    Article  CAS  PubMed Central  Google Scholar 

  67. Kereiakes DJ, Chrysant SG, Izzo JL Jr, et al. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol. 2012;11:134.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. da Silva M, Haag U, Guest JF, et al. Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Health Qual Life Outcomes. 2015;13:24.

    Article  Google Scholar 

  69. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of longterm treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertension. 2009;11(9):475–82.

    Article  CAS  Google Scholar 

  70. Kereiakes DJ, Chrysant SG, Izzo JL Jr, et al. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich). 2012;14(3):149–57.

    Article  CAS  Google Scholar 

  71. Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis. 2010;4(4):209–21.

    Article  CAS  PubMed  Google Scholar 

  72. Izzo JL Jr, Chrysant SG, Kereiakes DJ, et al. 24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J Clin Hypertens (Greenwich). 2011;13(12):873–80.

    Article  CAS  Google Scholar 

  73. Chrysant SG, Germino FW, Neutel JM. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups. Am J Cardiovasc Drugs. 2012;12(6):375–89.

    Article  CAS  PubMed  Google Scholar 

  74. Kerediakes DJ, Neutal J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 years and older. J Clin Hypertens. 2009;11(8):411–21.

    Article  Google Scholar 

  75. Germino FW, Neutel JM, Dubiel R, et al. Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension. Am J Cardiovasc. 1012;12(5):325–33.

    Google Scholar 

  76. Neutel JM, Kereiakes DJ, BENIFICIARY Investigators. An olmesartan-medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am J Cardiovasc Drugs. 2010;10(5):289–303.

    Article  CAS  PubMed  Google Scholar 

  77. Rosenbaum D, Girerd X. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension. Curr Med Res Opin. 2012;28(2):179–86.

    Article  CAS  PubMed  Google Scholar 

  78. Mendell J, Matsushima N, O’Reilly TE, et al. A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval. J Clin Pharmacol. 2016;56(4):484–91.

    Article  CAS  PubMed  Google Scholar 

  79. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs. 2007;67(9):1309–27.

    Article  CAS  PubMed  Google Scholar 

  80. Volpe M, Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag. 2012;8:371–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Chrysant SG. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. Postgrad Med. 2011;123(6):21–31.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The article was reviewed by: R. B. Shah, GMERS Medical College and Hospital, Gandhinagar, Gujarat, India; N. Yasmeen, Shadan College of Pharmacy, Hyderabad, India. During the peer review process, the manufacturer of OLM/OLM-based FDCs was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide. Drugs Ther Perspect 32, 369–380 (2016). https://doi.org/10.1007/s40267-016-0335-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0335-0

Keywords

Search

Navigation